Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.7% – Time to Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price fell 5.7% during mid-day trading on Wednesday . The stock traded as low as $43.23 and last traded at $43.5850. 25,847 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 59,378 shares. The stock had previously closed at $46.20.

Wall Street Analyst Weigh In

A number of brokerages have commented on NBTX. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Monday. UBS Group increased their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Finally, Guggenheim increased their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Stock Down 7.4%

The business has a 50 day moving average price of $35.60 and a two-hundred day moving average price of $27.24.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter. On average, analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC bought a new stake in Nanobiotix during the 4th quarter valued at $390,000. Marshall Wace LLP bought a new stake in Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. bought a new stake in Nanobiotix during the 3rd quarter valued at $101,000. Finally, Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.